EA201992001A1 - COMPOSITIONS AND METHODS FOR INCREASING GENE EXPRESSION - Google Patents

COMPOSITIONS AND METHODS FOR INCREASING GENE EXPRESSION

Info

Publication number
EA201992001A1
EA201992001A1 EA201992001A EA201992001A EA201992001A1 EA 201992001 A1 EA201992001 A1 EA 201992001A1 EA 201992001 A EA201992001 A EA 201992001A EA 201992001 A EA201992001 A EA 201992001A EA 201992001 A1 EA201992001 A1 EA 201992001A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
gene expression
compositions
increasing gene
increasing
Prior art date
Application number
EA201992001A
Other languages
Russian (ru)
Inventor
Аннахита Керавала
Original Assignee
Адверум Байотекнолоджис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адверум Байотекнолоджис, Инк. filed Critical Адверум Байотекнолоджис, Инк.
Publication of EA201992001A1 publication Critical patent/EA201992001A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении предложены полинуклеотидные кассеты, векторы экспрессии и способы экспрессии гена в клетках млекопитающих.The present invention provides polynucleotide cassettes, expression vectors and methods for gene expression in mammalian cells.

EA201992001A 2017-03-17 2018-03-16 COMPOSITIONS AND METHODS FOR INCREASING GENE EXPRESSION EA201992001A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472892P 2017-03-17 2017-03-17
PCT/US2018/022996 WO2018170473A1 (en) 2017-03-17 2018-03-16 Compositions and methods for enhanced gene expression

Publications (1)

Publication Number Publication Date
EA201992001A1 true EA201992001A1 (en) 2020-01-24

Family

ID=63523675

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992001A EA201992001A1 (en) 2017-03-17 2018-03-16 COMPOSITIONS AND METHODS FOR INCREASING GENE EXPRESSION

Country Status (14)

Country Link
US (3) US11773406B2 (en)
EP (1) EP3596213A4 (en)
JP (2) JP7343903B2 (en)
KR (1) KR102616820B1 (en)
CN (1) CN110546257B (en)
AU (1) AU2018234918B2 (en)
BR (1) BR112019019158A2 (en)
CA (1) CA3054942A1 (en)
EA (1) EA201992001A1 (en)
IL (1) IL268788B2 (en)
MX (1) MX2019011040A (en)
SG (1) SG11201907653QA (en)
WO (1) WO2018170473A1 (en)
ZA (1) ZA202310779B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
AU2017345470B2 (en) 2016-10-19 2023-08-03 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
EP3596213A4 (en) 2017-03-17 2021-02-17 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
AU2018372235B9 (en) * 2017-11-27 2022-03-10 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
WO2020025357A1 (en) * 2018-08-02 2020-02-06 Novozymes A/S Preparation of combinatorial libraries of dna constructs using introns
AU2020231505A1 (en) 2019-03-04 2021-08-19 Adverum Biotechnologies, Inc. Sequential intravitreal administration of AAV gene therapy to contralateral eyes
CA3131130A1 (en) * 2019-03-06 2020-09-10 Generation Bio Co. Non-active lipid nanoparticles with non-viral, capsid free dna
AU2020345915A1 (en) 2019-09-11 2022-03-24 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using AAV2 variants encoding aflibercept
BR112022003206A2 (en) * 2019-09-11 2022-08-16 Adverum Biotechnologies Inc METHODS TO TREAT NEOVASCULAR EYE DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPTE
US20210100856A1 (en) * 2019-09-11 2021-04-08 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
KR102798616B1 (en) * 2019-12-20 2025-04-22 (주)셀트리온 Expression cassette for expressing target protein highly and method for using the same
KR102346159B1 (en) * 2020-02-20 2022-01-03 국립암센터 High Efficiency Expression Vector and Uses thereof
DE102020111571A1 (en) 2020-03-11 2021-09-16 Immatics US, Inc. WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES
EP4127182A4 (en) * 2020-03-27 2024-07-31 Allen Institute ARTIFICIAL EXPRESSION CONSTRUCTS TO SELECTIVELY MODULATE GENE EXPRESSION IN NON-NEURAL BRAIN CELLS
US12173304B2 (en) * 2020-07-08 2024-12-24 Neuracle Genetics Inc. Intron fragments
CN113817775B (en) * 2020-08-25 2023-02-17 南京吉迈生物技术有限公司 Modified aflibercepts, compositions, methods and uses thereof in gene therapy
CN114250226A (en) * 2020-09-25 2022-03-29 北京安龙基因医药技术有限公司 Expression vectors for high-level expression of foreign genes
CN114250227A (en) * 2020-09-25 2022-03-29 北京安龙基因医药技术有限公司 Expression vectors for high-level expression of foreign genes
AU2022217778A1 (en) * 2021-02-02 2023-08-31 Allen Institute Artificial expression constructs for modulating gene expression in gabaergic neurons and astrocytes
EP4329721A1 (en) 2021-04-27 2024-03-06 Adverum Biotechnologies, Inc. Methods of treating ocular diseases using aav2 variants encoding aflibercept
AR126407A1 (en) * 2021-07-08 2023-10-11 Tenaya Therapeutics Inc OPTIMIZED EXPRESSION CASSETTES FOR GENO THERAPY
IL314298A (en) * 2022-01-31 2024-09-01 Trames Bio Inc Expression cassettes for treating epilepsy and neuropathic pain
IL314455A (en) 2022-02-02 2024-09-01 Adverum Biotechnologies Inc Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
EP4479098A1 (en) 2022-02-16 2024-12-25 Adverum Biotechnologies, Inc. Method of reducing cst fluctuation in neovascular amd by a recombinant adeno-associated virus
WO2023225455A2 (en) * 2022-05-18 2023-11-23 Visgenx, Inc. Synthetic aav genomes for improved gene delivery
EP4421176A4 (en) * 2022-12-29 2025-01-01 Themedium Therapeutics Co., Ltd NEW ELEMENT OF THE UNTRANSLATED 5' REGION AND ITS APPLICATION
WO2024211831A1 (en) 2023-04-05 2024-10-10 Adverum Biotechnologies, Inc. Immune landscape signatures for ocular inflammation
WO2025073297A1 (en) * 2023-10-06 2025-04-10 甘李药业股份有限公司 Aav virus vector expressing anti-vegf fusion protein and use of aav virus vector

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
DK0694042T3 (en) 1993-03-25 2005-02-14 Merck & Co Inc Vascular endothelial cell growth factor inhibitor
US20020168342A1 (en) 1994-11-03 2002-11-14 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
DE69824859T2 (en) 1997-04-14 2005-08-04 Cell Genesys, Inc., Foster City METHODS OF INCREASING THE EFFICIENCY OF RECOMBINANT AAV PRODUCTS
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2003012054A2 (en) 2001-08-02 2003-02-13 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
US8021875B2 (en) 2001-08-27 2011-09-20 Roche Madison Inc. Methods for expression of transgenes
AU2003223775A1 (en) 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
AU2003278695A1 (en) * 2002-05-28 2004-02-02 Maxygen, Inc. Nucleic acid vectors
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition
CA2514941A1 (en) 2003-02-03 2004-08-19 Immuno Japan Inc. High-expression vector for animal cells
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP1644508A1 (en) 2003-07-11 2006-04-12 Cytos Biotechnology AG Gene expression system
US20070196389A1 (en) 2005-11-18 2007-08-23 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
EP2205618B1 (en) * 2007-09-26 2016-11-09 Intrexon Corporation Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression
TWI478937B (en) 2008-01-15 2015-04-01 Abbvie Inc Improved mammalian expression vectors and uses thereof
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
PT3693025T (en) 2011-04-22 2022-01-20 Univ California Adeno-associated virus virions with variant capsid and methods of use thereof
TWI775096B (en) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 Treatment of amd using aav sflt-1
US8975042B2 (en) * 2012-12-21 2015-03-10 Dna Twopointo, Inc. Fluorescent and colored proteins and methods for using them
ES2897508T3 (en) 2013-05-31 2022-03-01 Univ California Adeno-associated virus variants and methods of using them
BR112016017817A2 (en) * 2014-02-06 2017-10-10 Genzyme Corp compositions and methods for the treatment and prevention of macular degeneration
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
ES2835673T3 (en) 2014-04-09 2021-06-22 Dna Twopointo Inc Improved nucleic acid constructs for eukaryotic gene expression
US10344285B2 (en) 2014-04-09 2019-07-09 Dna2.0, Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
HK1243922A1 (en) * 2014-11-05 2018-07-27 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
JP6544565B2 (en) * 2015-04-28 2019-07-17 国立大学法人広島大学 Method and kit for enhancing expression of target gene in mammalian cells and use thereof
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
EP3448437B1 (en) 2016-04-29 2021-12-29 Adverum Biotechnologies, Inc. Evasion of neutralizing antibodies by a recombinant adeno-associated virus
CN109844124B (en) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 Gene therapy for age-related diseases and disorders
CN109641065A (en) 2016-06-16 2019-04-16 阿德夫拉姆生物技术股份有限公司 Treatment of AMD using AAV2 variants and aflibercept
RS63282B1 (en) 2016-06-16 2022-06-30 Adverum Biotechnologies Inc Compositions and methods for reducing ocular neovascularization
AU2017345470B2 (en) 2016-10-19 2023-08-03 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
CA3054687A1 (en) 2017-02-28 2018-09-07 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
EP3596213A4 (en) 2017-03-17 2021-02-17 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression

Also Published As

Publication number Publication date
US20200010851A1 (en) 2020-01-09
EP3596213A4 (en) 2021-02-17
CN110546257B (en) 2024-03-01
KR102616820B1 (en) 2023-12-21
US11773406B2 (en) 2023-10-03
KR20190132626A (en) 2019-11-28
JP2022092057A (en) 2022-06-21
IL268788B1 (en) 2025-01-01
US11352644B2 (en) 2022-06-07
ZA202310779B (en) 2024-07-31
WO2018170473A1 (en) 2018-09-20
NZ756504A (en) 2023-11-24
AU2018234918B2 (en) 2023-11-02
SG11201907653QA (en) 2019-09-27
CN110546257A (en) 2019-12-06
JP7343903B2 (en) 2023-09-13
IL268788B2 (en) 2025-05-01
US20210040501A1 (en) 2021-02-11
BR112019019158A2 (en) 2020-05-05
JP2020513792A (en) 2020-05-21
AU2018234918A1 (en) 2019-09-12
EP3596213A1 (en) 2020-01-22
IL268788A (en) 2019-10-31
MX2019011040A (en) 2020-01-20
US20230257777A1 (en) 2023-08-17
CA3054942A1 (en) 2018-09-20
JP7360208B2 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
EA201992001A1 (en) COMPOSITIONS AND METHODS FOR INCREASING GENE EXPRESSION
CY1121217T1 (en) METHODS FOR HARVESTING MAMMAL CELL CULTURES
CY1123823T1 (en) IMPROVED T CELL COMPOSITIONS
SA517390590B1 (en) Modified Factor IX, and Compositions, Methods and Uses for Gene Transfer to Cells, Organs and Tissues
SA518391159B1 (en) Affinity-Oligonucleotide Conjugates and Uses Thereof
MX2023013342A (en) Car t cell therapies with enhanced efficacy.
SG10201810150UA (en) Compositions and methods for enhanced gene expression in cone cells
MX2023011785A (en) Methods and compositions for egg white protein production.
MX2019007021A (en) Il-11ra antibodies.
MY194032A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
EA201891202A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201891201A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890050A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890049A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890137A1 (en) MEDIUM FOR CULTIVATION OF CELLS WITH ADDITION OF TAURIN AND METHODS OF APPLICATION
MX2017003478A (en) Anti-fgfr2/3 antibodies and methods using same.
TR201810635T4 (en) Anti-jagged1 antibodies and methods of use.
EA201500943A1 (en) COMPOSITIONS FOR MOBILIZATION, HOUMING, REPRODUCTION AND DIFFERENTION OF STEM CELLS AND METHODS OF APPLICATION OF COMPOSITIONS
EA201990423A1 (en) HIGH PERFORMANCE CELL CAMERA SCREENING
MX2019000177A (en) Antibody formulations.
MX382997B (en) COMPOSITIONS AND METHODS FOR ENHANCING GENETIC EXPRESSION OF PKLR.
PL3601581T3 (en) Cell culture methods involving hdac inhibitors or rep proteins
BR112018009097A8 (en) spodoptera frugiperda resistant to vip3a
EA201791233A1 (en) STEM CELL MATERIAL AND METHOD FOR ITS PREPARATION
BR112018014940A2 (en) herbicide combination